Using the Systemic Immune-Inflammation Index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC)

Authors

Tithi Biswas, Case Western Reserve University
Kylie H Kang, Washington University School of Medicine in St. Louis
Rohin Gawdi, Wake Forest University
David Bajor, Case Western Reserve University
Mitchell Machtay, Penn State University
Charu Jindal, University of Newcastle
Jimmy T Efird, DVAHCS/Duke Affiliated Center

Journal

International Journal of Environmental Research and Public Health

Publication Date

2020

Volume

17

Issue

21

First Page

7995

Document Type

Open Access Publication

DOI

10.3390/ijerph17217995

Rights and Permissions

Biswas T, Kang KH, Gawdi R, et al. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Int J Environ Res Public Health. 2020;17(21):7995. doi:10.3390/ijerph17217995

Recommended Citation

Biswas, Tithi; Kang, Kylie H; Gawdi, Rohin; Bajor, David; Machtay, Mitchell; Jindal, Charu; and Efird, Jimmy T, "Using the Systemic Immune-Inflammation Index (SII) as a mid-treatment marker for survival among patients with stage-III locally advanced non-small cell lung cancer (NSCLC)." International Journal of Environmental Research and Public Health. 17, 21. 7995 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9945